Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis
Ritika Jaini1, Drew Hannaman, Justin M Johnson
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Summary
Gene transfer offers a promising alternative to multiple injections for multiple sclerosis (MS) therapy. A single gene therapy treatment effectively managed experimental autoimmune encephalomyelitis (EAE), an MS model, showing long-term benefits.
Area of Science:
- Neuroimmunology
- Gene Therapy
- Protein Therapeutics
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Current MS treatments often involve frequent recombinant interferon-beta (IFN-beta) injections.
- In vivo gene transfer presents a potential alternative for sustained protein delivery.
Purpose of the Study:
- To compare the therapeutic efficacy of electroporation (EP)-mediated intramuscular IFN-beta gene transfer with traditional recombinant IFN-beta injections.
- To evaluate the long-term therapeutic effects of a single IFN-beta gene transfer in an established animal model of MS.
Main Methods:
- Experimental autoimmune encephalomyelitis (EAE), an animal model for MS, was induced.
- Therapeutic interventions included a single intramuscular administration of an IFN-beta-expressing plasmid via electroporation (EP) or repeated alternate-day injections of recombinant IFN-beta (rIFN-beta).
- Control groups received no treatment or a null vector.
Main Results:
- A single EP-mediated intramuscular IFN-beta gene transfer resulted in long-term expression of interferon-inducible genes.
- IFN-beta gene delivery significantly inhibited disease progression and reduced relapses in established EAE.
- The therapeutic effects of gene delivery were comparable to an 8-week regimen of daily rIFN-beta injections.
Conclusions:
- EP-mediated intramuscular IFN-beta gene transfer is a viable and effective therapeutic strategy for established EAE.
- This gene-based approach offers a convenient alternative for long-term IFN-beta protein therapy in MS.
- The findings support the potential of gene therapy as a more clinically relevant treatment for MS.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...